Guardant Co-CEO 'Never Expected' 100 Million Covered Lives For Shield, As Test Volume Jumps 246%

Guardant raised its full-year screening outlook after Shield sales hit $68 million, though a billing-code gap will delay some cash.

Share
Guardant Co-CEO 'Never Expected' 100 Million Covered Lives For Shield, As Test Volume Jumps 246%

Guardant Health Co-CEO Amirali Talasaz said on the company's third-quarter earnings call Thursday that he never expected to be discussing coverage for about 100 million people for its Shield colorectal cancer blood test this soon. Shield revenue rose 180% to $68 million, and the company raised its full-year screening outlook.

Shield volume more than triples

Guardant, a precision oncology company that makes blood and tissue tests for cancer, reported third-quarter revenue of $361 million, up 36% from $265 million a year earlier. Shield tests grew 246% to 83,000, from 24,000.

Talasaz said he never expected to be "sitting here in Q3 earning call and talking about 100 million people, over 80% of the market for colorectal cancer screenings," with coverage for Shield. He expects it to be "a major growth driver" in coming quarters and years, though it will take time to show in the numbers.

He credited sales-rep productivity, national direct-to-consumer advertising and a co-promotion with Quest. Rep productivity is going up "in a very, very meaningful way," he said, and hiring continues, with another big class hoped for in early 2027.

CFO Mike Bell said full-year screening revenue guidance rises to $233 million to $238 million, with 285,000 to 290,000 Shield tests expected. Total 2026 revenue guidance rises to $1.36 billion to $1.37 billion.

Price and cost per test

Bell said Shield's average selling price stayed above $800, helped by Medicare and Medicare Advantage payments. As more commercially insured patients under 65 come on, he expects the price to dip somewhat, with a floor of $700.

Cost per test fell to $330 in the third quarter from $410 in the second, beating a year-end target of $350. Bell said the company is aiming for $200 by the end of 2028, aided by automation at a new Palo Alto lab scheduled to go live in 2027.

UnitedHealthcare and the cash delay

Asked by an Evercore ISI analyst about UnitedHealthcare, Talasaz said coverage has been in place since August 1 but contracting has not reached material progress. "Give us a few quarters," he said.

Bell raised the full-year free cash flow burn outlook to $205 million to $220 million, from $195 million to $205 million. He blamed a CMS delay in processing claims for the new Guardant360 Liquid CDX test, which uses a new billing code the agency cannot process until a system update in January 2027. About $10 million to $15 million in payments expected in the second half of 2026 will shift to the first half of 2027.

Third-quarter free cash flow burn was $37 million, against $46 million a year earlier, and cash and investments ended at $1.1 billion.

Bell said screening should reach an inflection point in 2027 and break even as a standalone business by the end of 2028, with company-wide free cash flow breakeven still targeted for the end of 2027.

Sources

More on Guardant Health

All Guardant Health (GH) coverage →